The ribosome, long regarded as a passive, uniform machine, has only recently been recognised as a direct regulator of translation. Mass spectrometry and sequencing approaches have shown that heterogeneity in ribosome composition exists, which can actively regulate the translational process. One source of this heterogeneity is the modification of ribosomal RNA (rRNA), primarily pseudouridylation (pseU) and 2′-O-methylation (2OMe), mediated by specific H/ACA and C/D box small nucleolar RNAs (snoRNAs). Here, we investigate how the stoichiometry of rRNA modifications varies during embryonic stem cell differentiation. Using the modification basecalling capability of Nanopore direct RNA sequencing, we have identified distinct stoichiometric changes in modification patterns between pluripotent and differentiated cells, revealing highly dynamic, site-specific regulation. Further, profiling of snoRNA expression during trilineage differentiation revealed differential expression of H/ACA and C/D box snoRNAs responsible for a subset of these dynamic modifications. By integrating rRNA and snoRNA sequencing approaches, we have built a comprehensive profile of rRNA modification dynamics during early embryonic cell fate decisions, highlighting potential regulatory mechanisms for ribosome heterogeneity during development. GRAPHICAL ABSTRACT
Tessa W. Y. Chan, Ivana Barbaric, Emma E. Thomson· bioRxiv· 0 citations
Charcot-Marie-Tooth disease (CMT) is a group of inherited progressive conditions affecting distal motor and sensory neurons, leading to muscle weakness, pain, and loss of sensation in limbs. CMT type 2A (CMT2A) is the most common form of axonal CMT and is associated with a more severe clinical manifestation. However, there are no treatments currently available. To investigate disease mechanisms and facilitate treatment discovery, we developed an in vitro model for CMT2A by introducing the patient-specific MFN2R94Q/+ variant into human embryonic stem cells (hESCs). Isogenic variant and wild-type hESCs differentiated into spinal motor neurons with similar efficiency and gave rise to functional motor neurons in vitro. However, MFN2R94Q/+ spinal motor neurons displayed impaired mitochondrial trafficking, resulting in altered distribution of mitochondria in axons. Unbiased quantitative proteomic profiling of the endogenous MFN2 interactome revealed dose-dependent remodelling by the R94Q variant across 412 proteins, highlighting candidate mechanisms in disease pathology. Importantly, we showed that mitochondrial trafficking defects could be alleviated by treatment with an HDAC6 inhibitor. Chemical inhibition of HDAC6 also rescued the motor phenotype in a zebrafish CMT2A model. Taken together, our study reveals a variant-specific insight into CMT2A disease mechanisms and confirms HDAC6 as a promising target for further therapeutic development.
Lydia H. Jestice, Larissa Butler, Rebecca A. Lea et al.· JCI Insight· 0 citations